The therapeutic potential of TNF-α blockade in rheumatoid arthritis

Expert Opinion on Investigational Drugs

Volumn 12, Issue 7, 2003, Pages 1087-1095

  Paleolog, Ewa ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Infliximab; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; ANGIOSTATIN; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; BEVACIZUMAB; BUCILLAMINE; CERTOLIZUMAB PEGOL; CHEMOKINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTHROPATHY; AUTOIMMUNE DISEASE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL INFILTRATION; CHRONIC DISEASE; DRUG MECHANISM; DRUG POTENCY; HUMAN; LEUKOCYTE; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM;

EID: 0037768899     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.7.1087     Document Type: Review

References (68)

1. LAWRENCE RC, HOCHBERG MC, KELSEY JL et al.: Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J. Rheumatol. (1989) 16:427-441.
2. HARRIS ED Jr: Pathogenesis of rheumatoid arthritis. Am. J. Med. (1986) 80:4-10.
3. GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. (2003) 48:54-58.
4. VAN DOORNUM S, MCCOLL G, WICKS IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. (2002) 46:862-873.
5. SOLOMON DH, KARISON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 107:1303-1307.
6. YELIN E: Arthritis. The cumulative impact of a common chronic condition. Arthritis Rheum. (1992) 35:489-497.
7. LEE DM, WEINBLATT ME: Rheumatoid arthritis. Lancet (2001) 358:903-911.
8. ROSS R: Atherosclerosis-an inflammatory disease. N. Engl. J. Med. (1999) 340:115-126.
9. DAYER JM, DE ROCHEMONTEIX B, BURRUS B, DEMCZUK S, DINARELLO CA: Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J. Clin. Invest. (1986) 77:645-648.
10. BUCALA R, RITCHLIN C, WINCHESTER R, CERAMI A: Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J. Exp. Med. (1991) 173:569-574.
11. DI GIOVINE FS, NUKI G, DUFF GW: Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. (1988) 47:768-772.
12. CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34:1125-1132.
13. AREND WP, DAYER JM: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. (1990) 33:305-315.
14. AREND WP, DAYER JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151-160.
15. FELDMANN M: Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. (2002) 2:364-371.
16. FELDMANN M, BRENNAN FM, FOXWELL BM, MAINI RN: The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr. Dir. Autoimmun. (2001) 3:188-199.
17. BRENNAN FM, CHANTRY D, JACKSON AM, MAINI RN, FELDMANN M: Cytokine production in culture by cells isolated from the synovial membrane. J. Autoimmun. (1989) 2(Suppl.):177-186.
18. CHU CQ, FIELD M, ALLARD S et al.: Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. (1992) 31:653-661.
19. DELEURAN BW, CHU CQ, FIELD M et al.: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. (1992) 35:1170-1178.
20. BRENNAN FM, CHANTRY D, JACKSON A, MAINI R, FELDMANN M: Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 2(8657):244-247.
21. BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. (1995) 6:225-230.
22. HAWORTH C, BRENNAN FM, CHANTRY D et al.: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. J. Immunol. (1991) 21:2575-2579.
23. WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1992) 89:9784-9788.
24. PIGUET PF, GRAU GE, VESIN C et al.: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology (1992) 77:510-514.
25. THORBECKE GJ, SHAH R, LEU CH et al.: Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen Type II arthritis in mice. Proc. Natl. Acad. Sci. USA (1992) 89:7375-7379.
26. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. (1993) 36:1681-1690.
27. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110.
28. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552-1563.
29. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932-1939.
30. CHARLES P, ELLIOTT MJ, DAVIS D et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. (1999) 163:1521-1528.
31. ULFGREN AK, ANDERSSON U, ENGSTROM M et al.: Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. (2000) 43:2391-2396.
32. PALEOLOG EM, HUNT M, ELLIOTT MJ et al.: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. (1996) 39:1082-1091.
33. TAK PP, TAYLOR PC, BREEDVELD FC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. (1996) 39:1077-1081.
34. TAYLOR PC, PETERS AM, PALEOLOG E et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. (2000) 43:38-47.
35. BALLARA SC, MIOTLA JM, PALEOLOG EM: New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int. J. Exp. Pathol. (1999) 80:235-250.
36. PALEOLOG EM: Angiogenesis in rheumatoid arthritis. Arthritis Res. (2002) 4(Suppl. 3):S81-S90.
37. NEUFELD G, COHEN T, GENGRINOVITCH S, POLTORAK Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. (1999) 13:9-22.
38. FAVA RA, OLSEN NJ, SPENCER-GREEN G et al.: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. (1994) 180:341-346.
39. KOCH AE, HARLOW LA, HAINES GK et al.: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. (1994) 152:4149-4156.
40. PALEOLOG EM, YOUNG S, STARK AC et al.: Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1258-1265.
41. TAYLOR PC: VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res. (2002) 4(Suppl. 3):S99-S107.
42. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. (2000) 343:1594-1602.
43. KALDEN-NEMETH D, GREBMEIER J, ANTONI C et al.: NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol. Int. (1997) 16:249-255.
44. BRENNAN FM, BROWNE KA, GREEN PA et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br. J. Rheumatol. (1997) 36:643-650.
45. MAINI RN, FELDMANN M: How does infliximab work in rheumatoid arthritis? Arthritis Res. (2002) 4(Suppl. 2):S22-S28.
46. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46:1443-1450.
47. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
48. CHOY EH, ISENBERG DA, GARROOD T et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. (2002) 46:3143-3150.
49. NUKI G, BRESNIHAN B, BEAR MB, MCCABE D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2838-2846.
50. FLEISCHMANN RM, SCHECHTMAN J, BENNETT R et al.: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. (2003) 48:927-934.
51. KAVANAUGH AF, DAVIS LS, JAIN RI et al.: A Phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. (1996) 23:1338-1344.
52. CHOY EH, PANAYI GS, EMERY P et al.: Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) (2002) 41:1142-1148.
53. PEACOCK DJ, BANQUERIGO ML, BRAHN E: Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. (1992) 175:1135-1138.
54. OLIVER SJ, CHENG TP, BANQUERIGO ML, BRAHN E: The effect of thalidomide and 2 analogs on collagen induced arthritis. J. Rheumatol. (1998) 25:964-969.
55. STORGARD CM, STUPACK DG, JONCZYK A et al.: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest. (1999) 103:47-54.
56. MIOTLA J, MACIEWICZ R, KENDREW J, FELDMANN M, PALEOLOG E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Invest. (2000) 80:1195-1205.
57. LU J, KASAMA T, KOBAYASHI K et al.: Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J. Immunol. (2000) 164:5922-5927.
58. SUMARIWALLA P, CAO Y, WU H, FELDMANN M, PALEOLOG E: The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res. Ther (2003) 5:R32-R39.
59. MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin. Oncol. (2001) 19:851-856.
60. NAGASHIMA M, YOSHINO S, AONO H, TAKAI M, SASANO M: Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin. Exp. Immunol. (1999) 116:360-365.
61. NAGASHIMA M, WAUKE K, HIRANO D et al.: Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) (2000) 39:1255-1262.
62. FELDMANN M, ANDREAKOS E, SMITH C et al.: Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann. Rheum. Dis. (2002) 61(Suppl. 2):II13-II18.
63. KIRIAKIDIS S, ANDREAKOS E, MONACO C et al.: VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase defective form of the IκB kinase 2. J. Cell Sci. (2003) 116:665-674.
64. ANDREAKOS E, SMITH C, KIRIAKIDIS S et al.: Heterogeneous requirement of IκB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum. (2003) (In press).
65. ANDREAKOS E, SMITH C, MONACO C et al.: IκB kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood (2003) 101:983-991.
66. CELLETTI FL, HILFIKER PR, GHAFOURI P, DAKE MD: Effect of human recombinant vascular endothelial growth factor 165 on progression of atherosclerotic plaque. J. Am. Coll. Cardiol. (2001) 37:2126-2130.
67. TAYLOR P, PATEL S, PALEOLOG E et al.: Reduced synovial vascularity following TNFα blockade in rheumatoid arthritis. Arthritis Rheum. (1998) 41(Suppl. 9):S295.
68. DAVIS D, CHARLES PJ, POTTER A et al.: Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br. J. Rheumatol. (1997) 36:950-956.